Pages that link to "Q2938837"
Jump to navigation
Jump to search
The following pages link to cariprazine (Q2938837):
Displaying 50 items.
- schizophrenia (Q41112) (← links)
- bipolar I disorder (Q4915474) (← links)
- Clinical potential of cariprazine in the treatment of acute mania (Q26992193) (← links)
- New developments in the management of schizophrenia and bipolar disorder: potential use of cariprazine (Q28083061) (← links)
- Effect of cariprazine across the symptoms of mania in bipolar I disorder: Analyses of pooled data from phase II/III trials (Q30999127) (← links)
- Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors. (Q34271094) (← links)
- Investigational drugs in recent clinical trials for treatment-resistant depression (Q34549390) (← links)
- A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia (Q34655540) (← links)
- An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial (Q34658836) (← links)
- Cariprazine exerts antimanic properties and interferes with dopamine D2 receptor β-arrestin interactions (Q35049564) (← links)
- Cariprazine in the treatment of schizophrenia: a proof-of-concept trial (Q36530048) (← links)
- Safety of antipsychotic drugs: focus on therapeutic and adverse effects (Q38224339) (← links)
- Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression (Q38305356) (← links)
- Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial (Q38397942) (← links)
- Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study (Q38418204) (← links)
- Serotonin 5-HT1A Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs (Q38516606) (← links)
- Cariprazine: First Global Approval (Q42700276) (← links)
- Long-term effects of cariprazine exposure on dopamine receptor subtypes (Q45829798) (← links)
- Vraylar (Q47522308) (← links)
- The dopamine D₃-preferring D₂/D₃ dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia (Q47584227) (← links)
- Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology (Q47589373) (← links)
- An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression (Q47920928) (← links)
- Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial. (Q48080525) (← links)
- Cariprazine delays ouabain-evoked epileptiform spikes and loss of activity in rat hippocampal slices (Q48087555) (← links)
- Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial (Q50246045) (← links)
- The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. (Q51318422) (← links)
- Cariprazine (RGH-188), a D₃-preferring dopamine D₃/D₂ receptor partial agonist antipsychotic candidate demonstrates anti-abuse potential in rats. (Q52301734) (← links)
- [Psychopharmacology of anxiety and depression: Historical aspects, current treatments and perspectives]. (Q53813267) (← links)
- Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia (Q63812652) (← links)
- Long-term Study of Cariprazine in Patients With Schizophrenia (Q63834785) (← links)
- Safety and Efficacy of RGH-188 in the Acute Exacerbation of Schizophrenia (Q64044049) (← links)
- Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia (Q64149736) (← links)
- A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia (Q64648986) (← links)
- Safety and Efficacy of Cariprazine in Schizophrenia (Q64655881) (← links)
- Safety and Efficacy of Cariprazine in Patients With Schizophrenia (Q64655883) (← links)
- Safety and Efficacy of Cariprazine for Mania (Q64656311) (← links)
- Long-term Safety and Tolerability of Cariprazine for Bipolar I Disorder (Q64658048) (← links)
- Safety and Efficacy of Cariprazine for Bipolar I Disorder (Q64658062) (← links)
- Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive Disorder (Q64679653) (← links)
- The Purpose of the Study is to Determine Whether Cariprazine is a Safe and Tolerated Long-term Treatment in Patients With Chronic Stable Schizophrenia (Q64694112) (← links)
- Cariprazine: Comparison of Slow- and Immediate-release Forms (Q65355326) (← links)
- An Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) (Q65374028) (← links)
- Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar Depression (Q65375479) (← links)
- Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia (Q65385408) (← links)
- Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I Depression (Q65404039) (← links)
- Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder (Q65404044) (← links)
- Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar Depression (Q65536903) (← links)
- To Evaluate the Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) (Q66343525) (← links)
- Cariprazine Pediatric ASD PK Study (Q94234955) (← links)
- (Q107366808) (redirect page) (← links)